阿托伐他汀对慢性阻塞性肺疾病合并肺动脉高压患者白介素17的影响及疗效观察

Effects of Atorvastatin on Interleukin-17 and Clinical Indicators in Patients with Severe Chronic Obstructive Pulmonary Disease Combined with Pulmonary Hypertension

目的:评价阿托伐他汀对重度慢性阻塞性肺疾病(COPD)合并肺动脉高压(PH)患者血清白介素17(IL-17)的影响及临床疗效。方法:收集我院23例重度稳定期COPD合并PH患者,随机分为观察组(10例)和对照组(13例)。对照组采用常规治疗,观察组在常规治疗基础上加用阿托伐他汀治疗。观察两组治疗前及治疗6个月后血清IL-17、超声心动图测量的肺动脉收缩压(PASP)、6min步行实验(6MWD)、第1秒钟用力呼气容积/用力肺活量百分比(FEV1/FVC)和FEV1占预计值百分比(FEV1%)的差异。结果:观察组血清IL-17、PASP较对照组降低(P<0.05);6MWD、FEV1/FVC和FEV1%则增加(P<0.05)。结论:在常规治疗的基础上联合阿托伐他汀治疗能降低IL-17水平,降低PASP,改善肺功能,提高COPD合并PH患者的运动耐量。

Objective：To evaluate the Atorvastatin curative effect on Interleukin-17 （IL-17） and clinical indicators in patients with severe chronic obstructive pulmonary disease （COPD） combined with pulmonary hypertension （PH）. Methods：Collecting 23 severe COPD patient with PH, randomly divided these patients in to observation group （10 patients） and controlled group （13 patients）. Both two groups were given routine way and the observation group were given atorvastatin （20mg/d） supplement in additional. Observe the change of the serum IL-17, pulmonary arterial systolic pressure （PASP） assessed by Doppler echocardiography, 6 minutes walk distance （6MWD）,the forced expiratory volume in one second/forced vital capacity （FEV1/FVC） ,and FEV1 % predicted （FEV1% pred） after 6 months were measured. Results.. In the observation group, the serum IL-17 and PASP decreased after 6 months compared with controlled group and before treatment in the same group （both P〈0. 05）, while 6MWD and FEV1/FVC, FEV1 %pred increased after 6 months （P〈0. 05）. There were no significant changes of above parameters in controlled group （P〈 0.05）. Conclusion.Atorvastatin can decrease IL-17 and PASP, which can improve lung function and the exercise tolerance of patients with COPD combined with PH.